Cargando…
Neuroleptic malignant syndrome in patients with COVID-19
We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory dis...
Autores principales: | Soh, Mitsuhito, Hifumi, Toru, Isokawa, Shutaro, Shimizu, Masato, Otani, Norio, Ishimatsu, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242930/ https://www.ncbi.nlm.nih.gov/pubmed/32473756 http://dx.doi.org/10.1016/j.ajem.2020.05.042 |
Ejemplares similares
-
The authors' response: A diagnostic confusion between serotonin syndrome and neuroleptic malignant syndrome
por: Soh, Mitsuhito, et al.
Publicado: (2021) -
The authors' response: Propofol in COVID 19: From basic science to clinical impact()
por: Soh, Mitsuhito, et al.
Publicado: (2021) -
The application of 6S in the care of COVID-19 patients: a Japanese perspective
por: Soh, Mitsuhito, et al.
Publicado: (2020) -
The authors’ response: Propofol and sedation in patients with coronavirus disease 2019
por: Soh, Mitsuhito, et al.
Publicado: (2021) -
Persistent Air Embolism after Blunt Chest Trauma with Recovery to Pre-Existing Consciousness Level: A Case Report and Literature Review
por: Soh, Mitsuhito, et al.
Publicado: (2022)